Astellas Pushes Further into Gene Therapy Field with US$3 B Audentes Buy
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)
Published: 6 Dec-2019
DOI: 10.3833/pdr.v2019.i12.2474 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Building its presence in gene therapy, Astellas has agreed to acquire Audentes Therapeutics, a clinical-stage company focused on treatments for rare neuromuscular diseases, for a total equity value of US$3 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS